Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis

Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: ACC-001 Clinical Trials Are Ongoing

(2017) J. Michael Ryan et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials

(2016) Jeff Sevigny et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease

(2016) Florence Pasquier et al.   JOURNAL OF ALZHEIMERS DISEASE

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

(2016) Ross Penninkilampi et al.   Journal of Neuroimmune Pharmacology

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice

(2016) Ksenia V. Kastanenka et al.   JOURNAL OF NEUROSCIENCE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

(2016) Marielle Delnomdedieu et al.   Alzheimers Research & Therapy

Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study

(2015) Jeff Sevigny et al.   Alzheimers & Dementia

2015 Alzheimer's disease facts and figures

(2015)   Alzheimers & Dementia

New Developments of Clinical Trial in Immunotherapy for Alzheimer's Disease

(2015) Cece Yang et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

(2015) Martin R Farlow et al.   Alzheimers Research & Therapy

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy

(2015) Jacopo C. DiFrancesco et al.   Frontiers in Neurology

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

(2014) Jeffrey Cummings et al.   Alzheimers & Dementia

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluating the Quality of Evidence from a Network Meta-Analysis

(2014) Georgia Salanti et al.   PLoS One

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities

(2013) Wagner Zago et al.   Alzheimers & Dementia

Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making

(2013) Shannon Cope et al.   BMC Medical Research Methodology

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease

(2013) Jaren W. Landen et al.   CLINICAL NEUROPHARMACOLOGY

2012: A watershed year for Alzheimer’s disease research

(2013) M. Grundman et al.   Journal of Nutrition Health & Aging

Graphical Tools for Network Meta-Analysis in STATA

(2013) Anna Chaimani et al.   PLoS One

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Gantenerumab for the treatment of Alzheimer's disease

(2012) Julien Delrieu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression

(2012) Ian R. White et al.   Research Synthesis Methods

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease

(2011) Kazunori Uenaka et al.   CLINICAL NEUROPHARMACOLOGY

Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

(2011) Jeroen P. Jansen et al.   VALUE IN HEALTH

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease

(2010) Francesco Panza et al.   Immunotherapy

GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology

(2010) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain

(2008) D. Boche et al.   BRAIN

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING